Structure Therapeutics Inc.

NASDAQ:GPCR

Biotechnology

Healthcare
$17.36 +0.86%

+$0.39 today

Market cap
$999.36M
Beta
-1.42
P/E (TTM)
-19.3
EPS (TTM)
-$2.35
52W Low $15.80High $94.90

Volume 1.10M

Average 0.87M

GPCR Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Structure Therapeutics Inc.NASDAQ: GPCR

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development growth accelerates

Q2 FY2026 research & development of $100.06M rose 82.9% year over year, ahead of the +79.9% change in trailing-twelve-month research & development. Sequentially, it rose 50.0% from the prior quarter. Over 3 fiscal years it compounded at +83.9% a year.

Context

  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +82.9% holds above the trailing-twelve-month pace of +79.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$100.06M+50.0% QoQ
Last fiscal yearDec 2025
$225.26M+107.0% YoY
LTMJun 2026
$294.44M+79.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+82.9%——
1 year+107.0%——
3-year CAGR+83.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
225.26M USD
Year-over-year change
+107.0%
4-year CAGR
+66.8%

Research & Development vs competitors

How GPCR compares with its peers on the latest reported figures

  • GPCR's LTM Jun 2026 research & development of $294.44M is the 2nd highest of the 8 companies compared; the peer median is $109.11M.
  • Its year-over-year change of +79.9% is the 2nd highest of 7, against a peer median of +46.4%.
  • Over three fiscal years its annual growth of +83.9% compares with a peer median of +13.1%.
GPCR Competitors Peer median
Research & Development for GPCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$301.59M +72.6%+71.3%—
GPCRStructure Therapeutics Inc.LTM Jun 2026$294.44M +79.9%+83.9%—
SEPNSepterna, Inc.LTM Sep 2026$132.66M +56.0%—137.8%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$114.57M +28.4%+7.1%572.9%
KLRAKailera Therapeutics, Inc.FY2025$109.11M ———
BIOABioAge Labs, Inc.LTM Mar 2026$83.27M +36.9%+34.3%807.2%
BMEABiomea Fusion, Inc.LTM Mar 2026$48.2M -55.0%-0.4%—
VTVTvTv Therapeutics Inc.LTM Mar 2026$24.01M +104.7%+13.1%65.2%
Peer median (excluding GPCR) $109.11M+46.4%+13.1%355.3%

Competitors are the stored peer set for GPCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00003.9M
Gross Profit0000(3.9M)
Gross Margin—————
Research & Development29.11M36.19M70.1M108.81M225.26M
Selling, General & Admin8.59M16.37M32.67M49.41M61.55M
Operating Expenses37.7M52.56M102.78M158.23M283.67M
Depreciation & Amortization72K277K295K992K3.9M
EBITDA(37.62M)(51.03M)(75.7M)(121.22M)(136.79M)
EBITDA Margin—————
Operating Income(37.7M)(52.56M)(102.78M)(158.23M)(287.57M)
Operating Margin—————
Interest Income1221.26M13.38M36.03M35.97M
Interest Expense122.16K013.39M00
Other Income / Expenses(122K)1.26M13.39M36.01M146.51M
Income Before Tax(37.82M)(51.3M)(89.38M)(122.22M)(140.69M)
Pre-Tax Margin—————
Income Tax Expense231K17K236K310K515K
Net Income(40.01M)(51.32M)(89.62M)(122.53M)(141.2M)
Net Margin—————
EPS (Basic)(1.20)(1.44)(2.43)(2.34)(2.40)
EPS (Diluted)(1.20)(1.44)(2.43)(2.34)(2.40)
Weighted Avg Shares36.59M36.59M36.73M52.64M59.2M
Weighted Avg Shares (Diluted)36.59M36.59M36.73M52.64M59.2M

Structure Therapeutics Inc.

NASDAQ:GPCR

Intrinsic Alpha fair value

Locked

Current Price

$17.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.